John Marshall, MD

Articles

Dr. Marshall on Early Data With Trastuzumab Deruxtecan in HER2+ CRC

May 6th 2021

John L. Marshall, MD, discusses early data reported with fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive colorectal cancer from the phase 2 DESTINY-CRC01 trial.

Dr. Marshall on the Emergence of Novel HER2-Targeted Agents in CRC

January 28th 2021

John L. Marshall, MD, discusses the emergence of novel HER2-targeted therapies for patients with colorectal cancer.

Dr. Marshall on Changes With Adjuvant Treatment in CRC

January 25th 2021

John L. Marshall, MD, discusses recent changes to the adjuvant treatment landscape in colorectal cancer.

Dr. Marshall on Challenges With Sequencing in CRC

October 15th 2020

John L. Marshall, MD, discusses ​sequencing challenges in colorectal cancer.

Dr. Marshall on the Importance of Molecular Testing in Gastrointestinal Cancers

July 13th 2020

John L. Marshall, MD, discusses the importance of molecular testing in gastrointestinal cancers.

Dr. John Marshall on Steps to Finding a Cure for Colorectal Cancer

December 21st 2015

John Marshall, MD, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses curing colorectal cancer.

Dr. John Marshall on the Importance of Molecular Profiling in Colorectal Cancer

November 10th 2015

John Marshall, MD, Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses the importance of molecular testing in colorectal cancer.